Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia

Phase IA/B Combination Study of ADI-PEG 20, Venetoclax and Azacitidine in Patients With Acute Myeloid Leukemia (AML)

Pegylated arginine deiminase (ADI-PEG 20) will be combined with venetoclax and azacitidine for treatment of subjects with previously treated or untreated with high risk factor acute myeloid leukemia (AML). Venetoclax and azacitidine are front-line therapy for such patients, and ADI-PEG 20 will be added to this regimen in a phase IA/B study.

Study Overview

• Status: Recruiting
• Conditions: Acute Myeloid Leukemia, Adult
• Intervention / Treatment: Drug: ADI-PEG 20

Detailed Description

This is an open label, single arm, phase 1 trial with recommended phase 2 dose (RP2D) cohorts based on subject inclusion criteria.

Lead In: 6 patients will be enrolled to be treated with standard dose of azacitidine and venetoclax and the expected RP2D of ADI-PEG 20 (dose level 0). In case of DLT occurring in >1 patient in cycle 1, 6 additional patients will be accrued at dose level -1 of ADI-PEG 20 while keeping the doses of azacitidine and venetoclax unchanged (Dose level -1). Enrollment to cohort 1 and 2 will start after ≤1 patient out of 6 encounters DLT in cycle 1 at one of these dose levels. The 6 patients enrolled at that dose level will be counted for efficacy analysis in Cohort 1. Cohort 1: Relapsed or refractory AML: target response 25%. Historical expectation for venetoclax and azacitidine is 15%.

Cohort 2: Newly diagnosed high risk AML: Target response 55%. Historical expectation for venetoclax and azacitidine is 40%.

Treatment may be continued for a total of 24 cycles, each of 28 days.

• Study Type: Interventional
• Enrollment (Anticipated): 60
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Mirla Langlois; Phone Number: 161 858-452-6688; Email: mlanglois@polarispharma.com
• Study Contact Backup: Name: Nicole DeFord; Phone Number: 619-808-5065; Email: ndeford@polarispharma.com

Study Locations

• United States
  • Illinois
    • Skokie, Illinois, United States, 60077
      • Recruiting
      • Orchard Healthcare Research Inc
      • Contact: Joy Jardinico, RN; Phone Number: 224-534-7580; Email: jjardinico@orchardhr.com
      • Contact: Ofelia Hernandez; Phone Number: 224-534-7580; Email: ohernandez@orchardhr.com
  • North Carolina
    • Charlotte, North Carolina, United States, 28204
      • Not yet recruiting
      • Levine Cancer Institute
      • Contact: Kelly Bumgarner, RN; Phone Number: 980-521-8696; Email: Kelly.Bumgarner@atriumhealth.org
      • Contact: Neha Upadhyay, RN; Phone Number: 980-442-2393; Email: Neha.Upadhyay@atriumhealth.org
  • Texas
    • Houston, Texas, United States, 77030
      • Recruiting
      • Md Anderson Cancer Center
      • Contact: Gautam Borthakur; Phone Number: 713-563-1586; Email: gborthak@mdanderson.org

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 99 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Cohort 1: Previously treated (relapsed/recurrent) or refractory AML based on the 2016 revision to the World Health Organization (WHO) criteria (Arber 2016)
• Cohort 2: Untreated AML per 2016 WHO (Arber 2016) criteria with high-risk features and not a candidate for intensive chemotherapy because of age 60 years or older, age-related comorbidities, cardiac disease, prior anthracycline use, high probability of treatment-related mortality, or otherwise would not benefit from intensive chemotherapy treatment.
• Age ≥ 18 years
• Life expectancy reasonably adequate for evaluating the treatment
• White blood cell (WBC) count of 10 × 109/L or less. (Use of hydroxyurea to control WBC is allowed till 48 hours prior to protocol treatment)
• Adequate renal function: Creatinine ≤ 1.5 x upper limit of normal (ULN) or creatinine clearance > 40 mL/minute (measured or calculated according to the Cockcroft-Gault formula)

• Adequate liver function

  • Total bilirubin ≤ 1.5 x ULN
  • ALT and AST both ≤ 2.5 x institutional ULN or ≤ 5 times the ULN for patients with leukemic involvement of liver

Exclusion Criteria:

• Prior treatments as follows:

  1. Cohort 1: >2 cycles of prior combination treatment with venetoclax+hypomethelating agent (i.e. azacitidine, decitabine) is exclusionary. All other prior treatment for antecedent hematological disorders and/or for AML is permitted.
  2. Cohort 2: Prior treatment for antecedent hematological disorders with venetoclax or chemotherapy or any prior treatment for their AML is exclusionary. However, treatment with other agents, including hydroxyurea or ≤2 cycles of hypomethylating agent (i.e. azacitidine, decitabine), for MDS or myeloproliferative neoplasm is permitted.
• Cohort 2: Favorable risk AML per European LeukemiaNet (ELN) 2022 criteria (Döhner 2022)
• Known active CNS involvement by leukemia

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Previously Treated AML; Previously treated AML based on the revised 2017 European LeukemiaNet (ELN) criteria with age at least 18 years, and having ≥10% blasts in bone marrow or peripheral blood	Drug: ADI-PEG 20; ADI-PEG 20 in combination with venetoclax and azacitidine; Other Names: Azacitidine; Venetoclax
Experimental: Untreated AML With High Risk Features; Untreated AML per ELN criteria with high risk features, or age ≥ 65 years and ineligible for intensive chemotherapy because of older than 75 years, cardiac disease or prior anthracycline use or high probability of treatment-related mortality	Drug: ADI-PEG 20; ADI-PEG 20 in combination with venetoclax and azacitidine; Other Names: Azacitidine; Venetoclax

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Determine the RP2D of ADI-PEG 20 in combination with venetoclax and azacitidine, per the number of subjects with treatment-related adverse events by current CTCAE	6 months

Secondary Outcome Measures

Outcome Measure	Time Frame
Determine preliminary evidence of tumor activity, per the revised 2017 European LeukemiaNet criteria	2 years
Determine the peripheral blood arginine levels of ADI-PEG 20 in combination with venetoclax and azacitidine	2 years
Determine the peripheral blood citrulline levels of ADI-PEG 20 in combination with venetoclax and azacitidine	2 years
Determine the anti-drug antibodies of ADI-PEG 20 in combination with venetoclax and azacitidine	2 years

Collaborators and Investigators

• Sponsor: Polaris Group
• Investigators: Study Director: John S Bomalaski, Polaris Group

Study record dates

Study Major Dates

• Study Start (Actual): April 5, 2022
• Primary Completion (Anticipated): July 1, 2025
• Study Completion (Anticipated): December 1, 2025

Study Registration Dates

• First Submitted: July 26, 2021
• First Submitted That Met QC Criteria: August 3, 2021
• First Posted (Actual): August 12, 2021

Study Record Updates

• Last Update Posted (Actual): May 11, 2023
• Last Update Submitted That Met QC Criteria: May 9, 2023
• Last Verified: May 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Venetoclax; Azacitidine
• Other Study ID Numbers: POLARIS2020-002

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No